NCT06028633 2023-09-13
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Peking University First Hospital
Phase 2 Not yet recruiting
Clinical Trials
1 trialsNot yet recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × 130-nm albumin-bound paclitaxel × Clear all